Table 2.
List of current clinical trials utilizing immunotherapy for the treatment of DMG.
| Study Title | Tumor Type | Vaccine Type | Clinical Trial ID | Pediatric or Adult | Status | Clinical Trial Phase |
|---|---|---|---|---|---|---|
| Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma (ADDICT-pedGLIO) | HGG, DIPG | Dendritic cell | NCT04911621 | Pediatric | Recruiting | 1/2 |
| Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma | DIPG | Tumor Lysate | NCT01400672 | Both | Terminated | 1 |
| Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO) | DIPG, Brain Stem Glioma | TTRNA-DC with GM-CSF, TTRNA-xALT plus Td | NCT03396575 | Both | Recruiting | 1 |
| Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma (ENACTING) | DIPG | Histone H3.3-K27M Neoantigen | NCT04749641 | Both | Recruiting | 1 |
| PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed PediatricHGG and DIPG and Recurrent MB | HGG, DIPG, Recurrent MB | PEP-CMV, Tetanus Diphtheria | NCT05096481 | Pediatric | Not yet recruiting | 2 |
| H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | DIPG, Glioma, DMG, H3 K27M-mutant | K27M peptide plus Nivolumab | NCT02960230 | Pediatric | Recruiting | 1/2 |
| rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | DIPG, DMG, H3 K27M-mutant | rHSC-DIPGVax with Balstilimab and Zalifrelimab | NCT04943848 | Pediatric | Not yetrecruiting | 1 |
| A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas (INTERCEPT-H3) | H3-mutated Glioma (newly diagnosed) | H3K27M peptide | NCT04808245 | Adult | Not yet recruiting | 1 |
| A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020) | Ependymoma, Ewing Sarcoma, HGG, Leukemia/Lymphoma, MB, Miscellaneous Brain/Solid Tumors, Neuroblastoma, Malignant Neoplasms (relapsed, refractory), Rhabdomyosarcoma | Nivolumab | NCT04730349 | Both | Not yet recruiting | 1/2 |
DMG = diffuse midline gliomas; HGG = high grade glioma; MB = medulloblastoma